ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 19940299

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.

Pescovitz MD and 17 others. N Engl J Med, 2009. Cited by 863 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. Papers, record 19940299. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19940299

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
PubMed
Journal
N Engl J Med
PubMed
Year
2009
PubMed
Publication types
Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
863
iCite
Relative citation ratio, by iCite
19.1
iCite
Revised in PubMed
2026-01-28
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pescovitz MDMark D
2Greenbaum CJCarla J
3Krause-Steinrauf HHeidi
4Becker DJDorothy J
5Gitelman SEStephen E
6Goland RRobin
7Gottlieb PAPeter A
8Marks JBJennifer B
9McGee PFPaula F
10Moran AMAntoinette M

1 to 10 of 18Source PubMed

See all 18 authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
B-LymphocytesMajor topic
Diabetes Mellitus, Type 1Major topic
Immunologic FactorsMajor topic
Insulin-Secreting CellsMajor topic
Adolescent
Adult
Antibodies, Monoclonal, Murine-Derived
Area Under Curve
C-Peptide
Child
Double-Blind Method
Female
Glycated Hemoglobin
Humans
Immunoglobulin M
Male
Rituximab
Young Adult

Source PubMed

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R21 DK077329NIDDK NIH HHSUnited StatesR21DK077329PubMed and NIHNIH RePORTER
U01 DK061034NIDDK NIH HHSUnited StatesU01DK061034PubMed and NIHNIH RePORTER
U01 DK061058NIDDK NIH HHSUnited StatesU01DK061058PubMed and NIHNIH RePORTER
U01 DK103282NIDDK NIH HHSUnited StatesU01DK103282PubMed and NIHNIH RePORTER

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00279305Rituximab in New Onset Type 1 DiabetesResultsYesClinicalTrials.gov
NCT02131675Detection of C-peptide in Youth With Longstanding Type 1 Diabetes MellitusBackgroundClinicalTrials.gov

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in20,181,981Rituximab, B-lymphocyte depletion, and beta-cell function.https://conductscience.org/library/papers/20181981

Source PubMed

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118,759,293Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.Arthritis Rheum2008https://conductscience.org/library/papers/18759293PubMed
211,717,199
Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations.
Int Immunol2001https://conductscience.org/library/papers/11717199PubMed
310,072,558Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis.J Immunol1999https://conductscience.org/library/papers/10072558PubMed
41,588,978Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.N Engl J Med1992https://conductscience.org/library/papers/1588978PubMed
58,109,842Lessons learned from use of cyclosporine for insulin-dependent diabetes mellitus. The case for immunotherapy for insulin-dependent diabetics having residual insulin secretion.Ann N Y Acad Sci1993https://conductscience.org/library/papers/8109842PubMed
65,129,308Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases.J Clin Invest1971https://conductscience.org/library/papers/5129308PubMed
717,943,078Rituximab treatment of idiopathic membranous nephropathy.Kidney Int2008https://conductscience.org/library/papers/17943078PubMed
88,750,784Progress in the immunointervention of type-1 diabetes mellitus.Horm Metab Res1995https://conductscience.org/library/papers/8750784PubMed
915,334,472B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.Arthritis Rheum2004https://conductscience.org/library/papers/15334472PubMed
1016,649,186
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Arthritis Rheum2006https://conductscience.org/library/papers/16649186PubMed

1 to 10 of 34

See all 34 references

Cited by566

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 863 citations.

PMIDTitleJournalYearIn PapersSource
42,974,164T cells in type 1 diabetes: mechanisms of β-cell autoimmunity, innate-adaptive immune crosstalk, and translational immunotherapy.Front Immunol2026https://conductscience.org/library/papers/42974164PubMed
42,857,072Complete remission after rituximab therapy of pemphigus: Real-world evidence on dosing regimens and retreatment strategies.JID Innov2026https://conductscience.org/library/papers/42857072PubMed
42,836,088Hyaluronan Accumulates in Inflamed Lymph Nodes and Promotes B-Cell Activation.Proteoglycan Res2025https://conductscience.org/library/papers/42836088PubMed
42,737,905Combined Exendin-4 and Rituximab Treatment Improves β-Cell Function and Delays Disease Progression in NOD Mice.Biology (Basel)2026https://conductscience.org/library/papers/42737905PubMed
42,661,296B Lymphocytes in Latent Autoimmune Diabetes in Adults: From Autoimmune Activation to Immunometabolic Heterogeneity and Precision Therapeutic Perspectives.Diabetes Metab Res Rev2026https://conductscience.org/library/papers/42661296PubMed
42,517,907[Immunotherapy and cell therapy in type 1 diabetes : Current state of research].Inn Med (Heidelb)2026https://conductscience.org/library/papers/42517907PubMed
42,496,430Type 1 Diabetes Mellitus Pathogenesis: Mechanisms, Early Diagnostic Strategies, and Emerging Therapeutic Approaches.Pathophysiology2026https://conductscience.org/library/papers/42496430PubMed
42,432,282Age-independent immune subtypes in type 1 diabetes exhibit distinct post-onset progression rates and immunotherapeutic responses.Diabetologia2026https://conductscience.org/library/papers/42432282PubMed
42,351,764Diabetes Therapeutics Beyond Hyperglycaemia: Toward Biological Systems Redesign.Biomedicines2026https://conductscience.org/library/papers/42351764PubMed
42,283,716Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect Profile.Diabetes Care2026https://conductscience.org/library/papers/42283716PubMed

1 to 10 of 566

See all 566 cited by

Genes10

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
HLA-A3,105PubTator's text mininghttps://conductscience.org/library/genes/3105NCBI Gene
HLA-DQA13,117PubTator's text mininghttps://conductscience.org/library/genes/3117NCBI Gene
HLA-DQB13,119PubTator's text mininghttps://conductscience.org/library/genes/3119NCBI Gene
HLA-DRB13,123PubTator's text mininghttps://conductscience.org/library/genes/3123NCBI Gene
HLA-DRB43,126PubTator's text mininghttps://conductscience.org/library/genes/3126NCBI Gene
INS3,630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene
KRT2054,474PubTator's text mininghttps://conductscience.org/library/genes/54474NCBI Gene
PTPRN5,798PubTator's text mininghttps://conductscience.org/library/genes/5798NCBI Gene
TNFRSF258,718PubTator's text mininghttps://conductscience.org/library/genes/8718NCBI Gene

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
RITUXIMABCHEMBL1201576Results1https://conductscience.org/library/drugs/CHEMBL1201576

Source ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19940299

GET https://conductscience.org/api/papers/v1/19940299/references?page=2

API referenceFor AI assistants